Linked Life Data

2190731

Source:http://linkedlifedata.com/resource/pubmed/id/2190731

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1990-7-19
pubmed:abstractText
Though the reported experience with zidovudine in human pregnancies is very limited, it would seem unreasonable at this time to withhold zidovudine therapy for fetal considerations in the treatment of pregnant women with AIDS and ARC. Whether the treatment of HIV-positive women with zidovudine at any time during pregnancy reduces the risk of perinatal transmission is unknown. Therefore, the use of zidovudine for that indication should await the results of controlled trials. At present, if zidovudine therapy is required during pregnancy, the standard dosage of 200 mg every 4 hours should be used. The woman and her fetus should be monitored carefully for signs of toxicity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0009-9201
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
276-89
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Antiviral therapy in pregnancy.
pubmed:affiliation
Department of OB/GYN, University of Washington, Seattle 98195.
pubmed:publicationType
Journal Article, Review